HIV Viral Dynamics of Lopinavir/Ritonavir Monotherapy as Second-Line Treatment: A Prospective, Single-Arm Trial

HIV Viral Dynamics of Lopinavir/Ritonavir Monotherapy as Second-Line Treatment: A Prospective, Single-Arm Trial

Background: Characterizing viral response to lopinavir/ritonavir (LPV/r) monotherapy as second-line treatment may guide recommendations for resource-limited settings (RLS). Methods: We conducted a 48-week prospective, single-arm study of LPV/r monotherapy in patients failing first-line therapy in Ni...

Full description

Bibliographic Details
Main Authors:	Cassidy W. Claassen MD, MPH, David Keckich MD, Chidi Nwizu MBBS, Alash’le Abimiku PhD, Donald Salami MPH, Michael Obiefune MBBS, Bruce L. Gilliam MD, Anthony Amoroso MD
Format:	Article
Language:	English
Published:	SAGE Publishing 2019-01-01
Series:	Journal of the International Association of Providers of AIDS Care
Online Access:	https://doi.org/10.1177/2325958218823209

Similar Items

Long-Term Outcome of Second-Line Antiretroviral Therapy in Resource-Limited Settings
by: Olukemi Osinusi-Adekanmbi MD, MPH, et al.
Published: (2014-07-01)

Lopinavir/ritonavir dosing during pregnancy in Brazil and maternal/infant laboratory abnormalities
by: Mario Ferreira Peixoto, M.D., et al.
Published: (2011-05-01)

Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients.
by: Nicola Gianotti, et al.
Published: (2017-01-01)

Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory study.
by: José R Santos, et al.
Published: (2013-01-01)

Recurrent oedema associated with the co-formulation of lopinavir and ritonavir Edema recorrente associado à co-formulação de lopinavir e ritonavir
by: Jorge Francisco C. Pinto, et al.
Published: (2004-08-01)

Toxicity for warfarine switching from lopinavir/ritonavir to dolutegravir
by: Ana Pelufo-Pellicer, et al.
Published: (2017-03-01)

Modulations of human placental transfer of lopinavir, ritonavir and enfuvirtide
by: Farinotti Robert, et al.
Published: (2010-05-01)

Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure
by: Nilkamhang Samruay, et al.
Published: (2009-12-01)

Long-term treatment outcomes of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who experienced NRTI and NNRTI failure
by: Manosuthi Weerawat, et al.
Published: (2012-03-01)

COVID-19 Hastalarında Lopinavir/Ritonavir ve Favipravir Deneyimi
by: Esma Eroğlu, et al.
Published: (2020-12-01)

Lopinavir/ritonavir for COVID-19: A living systematic review
by: Francisca Verdugo-Paiva, et al.
Published: (2020-07-01)

Cardio-metabolic effectsof HIV protease inhibitors (lopinavir/ritonavir).
by: Kathleen M S E Reyskens, et al.
Published: (2013-01-01)

Lopinavir/ritonavir in the treatment of HIV-1 infection: a review
by: Ashish Chandwani, et al.
Published: (2008-09-01)

Stavudine-induced pancreatitis followed by lopinavir-ritonavir-induced pancreatitis
by: Anand H, et al.
Published: (2008-01-01)

Maculopapular rash in COVID-19 patient treated with lopinavir/ritonavir
by: Paula Mazan, et al.
Published: (2020-05-01)

355 Lopinavir/ritonavir treatment in paediatric patients with covid-19
by: P Ip, et al.
Published: (2021-04-01)

COVID-19 Hastalarında Lopinavir/Ritonavir ve Favipravir Deneyimi
by: Şule Özdemir, et al.
Published: (2020-12-01)

Correction: Cardio-Metabolic Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir)
by: Kathleen M. S. E. Reyskens, et al.
Published: (2013-01-01)

Efavirenz and Lopinavir/Ritonavir Alter Cell Cycle Regulation in Lung Cancer
by: Rahaba Marima, et al.
Published: (2020-08-01)

Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial?
by: Adewale Bayode Owa, et al.
Published: (2020-10-01)

Correction: Cardio-Metabolic Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir).
by: Kathleen M. S. E. Reyskens, et al.
Published: (2013-01-01)

HPTLC Method for Simultaneous Determination of Lopinavir and Ritonavir in Capsule Dosage Form
by: A. V. Sulebhavikar, et al.
Published: (2008-01-01)

Novel strategies in the use of lopinavir/ritonavir for the treatment of HIV infection in children
by: Beatriz Larru Martinez, et al.
Published: (2010-03-01)

Hypertriglyceridaemia and the risk of pancreatitis six months post lopinavir/ritonavir initiation
by: Wilhelm P. Greffrath, et al.
Published: (2018-06-01)

The maladaptive effects of HIV protease inhibitors (Lopinavir/Ritonavir) on the rat heart.
by: Reyskens, Kathleen Maria Simone Elise
Published: (2013)

Lopinavir/Ritonavir for COVID-19: a Systematic Review and Meta-Analysis
by: Bahman Amani, et al.
Published: (2021-05-01)

Three Novel COVID-19 Pneumonia Cases Successfully Treated With Lopinavir/Ritonavir
by: Tatsuhiko Wada, et al.
Published: (2020-05-01)

Data on compounding lopinavir and ritonavir suspension for non-cooperative COVID-19 patients
by: D. Zanon, et al.
Published: (2020-12-01)

Lopinavir/ritonavir dosing during pregnancy in Brazil and maternal/infant laboratory abnormalities
by: Mario Ferreira Peixoto, et al.

USE OF LOPINAVIR/RITONAVIR ASSOCIATED WITH ERGOTAMINE RESULTING IN FOOT AMPUTATION: BRIEF COMMUNICATION
by: Fernando Raphael de Almeida Ferry, et al.
Published: (2014-06-01)

Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment
by: Paola Magro, et al.
Published: (2021-03-01)

High quality of life, treatment tolerability, safety and efficacy in HIV patients switching from triple therapy to lopinavir/ritonavir monotherapy: A randomized clinical trial.
by: Juan Pasquau, et al.
Published: (2018-01-01)

QT interval and arrhythmic safety of hydroxychloroquine monotherapy in coronavirus disease 2019
by: Arun R. Sridhar, MBBS, MPH, et al.
Published: (2020-08-01)

Low Third-Trimester Serum Levels of Lamivudine/Zidovudine and Lopinavir/Ritonavir in an HIV-Infected Pregnant Woman with Gastric Bypass
by: David E. Michalik DO, et al.
Published: (2015-03-01)

A Single-Arm, Proof-Of-Concept Trial of Lopimune (Lopinavir/Ritonavir) as a Treatment for HPV-Related Pre-Invasive Cervical Disease.
by: Lynne Hampson, et al.
Published: (2016-01-01)

Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019
by: Ji-Won Kim, et al.
Published: (2021-03-01)

Acute Kidney Injury Associated With Lopinavir/Ritonavir Combined Therapy in Patients With COVID-19
by: Yannick Binois, et al.
Published: (2020-10-01)

Stavudine-induced pancreatitis followed by lopinavir-ritonavir-induced pancreatitis: Is co-trimoxazole the culprit?
by: Bhargava P
Published: (2008-01-01)

Maternal Lopinavir/Ritonavir Is Associated with Fewer Adverse Events in Infants than Nelfinavir or Atazanavir
by: Christiana Smith, et al.
Published: (2016-01-01)

Simultaneous determination of plasma lopinavir and ritonavir by chemometrics-assisted spectrophotometry and comparison with HPLC method
by: Chutima Matayatsuk Phechkrajang
Published: (2013-06-01)